Novavax, European Commission and COVID-19
Novavax Gets EU Authorization for Updated COVID Vaccine Targeting JN.1 Strain
(Reuters) -The European Commission authorized Novavax's updated COVID-19 vaccine targeting the JN.1 strain of coronavirus in the region, the company said on Wednesday. The authorization is for use in individuals 12 years of age and older.
Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the European Commission granted Marketing Authorization for Novavax's updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine (recombinant,
Novavax (NVAX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mayank Mamtani ...
The most recent trading session ended with Novavax (NVAX) standing at $12.91, reflecting a +1.77% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a ...
We recently compiled a list of the 7 Best Under The Radar Stocks to Buy According to Analysts. In this article, we are going ...
The FDA recently approved the updated mRNA Pfizer and Moderna boosters, as well as the updated Novavax COVID vaccine, to ...
Novavax's financial position improved significantly with a $570 million cash infusion from Sanofi. Find out why I remain ...
This health news roundup covers various topics including Gerresheimer's stock jump due to an activist investor, a US list of ...
Novavax Inc (NVAX) reports significant revenue from Sanofi partnership and outlines strategic shifts to enhance future growth ...
Novavax says the European Commission granted Marketing Authorization for its updated 2024-2025 Nuvaxovid COVID-19 vaccine. NVX-CoV2705 is an updated version of Novavax's prototype COVID-19 vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback